"RV 144, \u00E9 o nome de um ensaio cl\u00EDnico tailand\u00EAs de uma vacina contra o HIV combinando duas vacinas mais antigas que falharam sozinhas. O teste foi lan\u00E7ado em outubro de 2003, ele testou uma estrat\u00E9gia de combate \u00E0 infec\u00E7\u00E3o de dois tiros usando medicamentos feitos pela Sanofi-Pasteur de Lyon, Fran\u00E7a, e VaxGen de Brisbane, Austr\u00E1lia. Ao longo de 24 semanas, os participantes receberam quatro doses de uma vacina \"primer\"; um v\u00EDrus de aves com defici\u00EAncia contendo vers\u00F5es sint\u00E9ticas de tr\u00EAs genes do HIV; e duas doses de um \"refor\u00E7o\", que consistia em uma prote\u00EDna chamada gp120, um componente principal do revestimento externo do HIV. Os m\u00E9dicos testaram a infec\u00E7\u00E3o pelo HIV a cada 6 meses durante 3 anos. O relat\u00F3rio inicial mostrou que a taxa de infec\u00E7\u00E3o por HIV entre os volunt\u00E1rios que receberam a vacina experimental foi 31% menor do que a taxa de infec\u00E7\u00E3o por HIV em volunt\u00E1rios que receberam o placebo. No entanto, a redu\u00E7\u00E3o n\u00E3o foi grande o suficiente para o Minist\u00E9rio da Sa\u00FAde da Tail\u00E2ndia apoiar a aprova\u00E7\u00E3o da vacina; foi relatado em 2019 que o teria licenciado se a redu\u00E7\u00E3o fosse de 50% ou mais. Os colaboradores do estudo declararam que os resultados deste estudo forneceram a primeira evid\u00EAncia de apoio de qualquer vacina sendo eficaz na redu\u00E7\u00E3o do risco de contrair o HIV. Em 20 de outubro de 2009, os organizadores divulgaram os resultados completos do estudo atrav\u00E9s da publica\u00E7\u00E3o no New England Journal of Medicine e os apresentaram na AIDS Vaccine Conference em Paris."@pt . . . . . "RV 144, or the Thai trial, was an HIV vaccine clinical trial that was conducted in Thailand between 2003 and 2006. It used a combination of two HIV vaccines that had each failed in earlier trials. Participants were vaccinated over the course of 24 weeks beginning in October 2003 and were then tested for HIV until July 2006. The results of the study were publicized in September 2009. The initial report showed that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. This reduction was not large enough for the Ministry of Public Health in Thailand to support approving the vaccine; it would have licensed it if the reduction had been 50% or more. The trial collaborators have stated that results of this trial give the first supporting evidence of any vaccine being effective in lowering the risk of contracting HIV. On October 20, 2009, the organizers released full results of the study through publishing in the New England Journal of Medicine and presented them at the AIDS Vaccine Conference in Paris."@en . . . . . . . . . . . . . . . . . "RV 144"@en . . . . . . "24470730"^^ . . . . . . . . . . . . . . . "RV 144, \u00E9 o nome de um ensaio cl\u00EDnico tailand\u00EAs de uma vacina contra o HIV combinando duas vacinas mais antigas que falharam sozinhas. O teste foi lan\u00E7ado em outubro de 2003, ele testou uma estrat\u00E9gia de combate \u00E0 infec\u00E7\u00E3o de dois tiros usando medicamentos feitos pela Sanofi-Pasteur de Lyon, Fran\u00E7a, e VaxGen de Brisbane, Austr\u00E1lia. Ao longo de 24 semanas, os participantes receberam quatro doses de uma vacina \"primer\"; um v\u00EDrus de aves com defici\u00EAncia contendo vers\u00F5es sint\u00E9ticas de tr\u00EAs genes do HIV; e duas doses de um \"refor\u00E7o\", que consistia em uma prote\u00EDna chamada gp120, um componente principal do revestimento externo do HIV. Os m\u00E9dicos testaram a infec\u00E7\u00E3o pelo HIV a cada 6 meses durante 3 anos. O relat\u00F3rio inicial mostrou que a taxa de infec\u00E7\u00E3o por HIV entre os volunt\u00E1rios que receberam"@pt . . . . . "RV 144"@pt . . . . . . "1095170634"^^ . "17625"^^ . . . "RV 144, or the Thai trial, was an HIV vaccine clinical trial that was conducted in Thailand between 2003 and 2006. It used a combination of two HIV vaccines that had each failed in earlier trials. Participants were vaccinated over the course of 24 weeks beginning in October 2003 and were then tested for HIV until July 2006. The results of the study were publicized in September 2009. The initial report showed that the rate of HIV infection among volunteers who received the experimental vaccine was 31% lower than the rate of HIV infection in volunteers who received the placebo. This reduction was not large enough for the Ministry of Public Health in Thailand to support approving the vaccine; it would have licensed it if the reduction had been 50% or more."@en . . . . . . .